Clinical Trials
3
Active:1
Completed:1
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Ovarian CancerSolid TumorMelanomaNon Small Cell Lung CancerPancreatic CancerPapillary Thyroid CancerColorectal Adenocarcinoma
- Interventions
- Drug: CM-24, Nivolumab, and Nal-IRI/5-FU/LV - ExpansionDrug: CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - ExpansionDrug: Nivolumab, Nab paclitaxel and Gemcitabine - ExpansionDrug: CM-24 and Nivolumab - Dose Escalation
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Famewave Ltd.
- Target Recruit Count
- 79
- Registration Number
- NCT04731467
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸Yale University, New Haven, Connecticut, United States
Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
Phase 1
Terminated
- Conditions
- Bladder CancerOvarian CancerNon-small Cell Lung Carcinoma (NSCLC)MelanomaColorectal CancerGastric Cancer
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2020-08-27
- Lead Sponsor
- Famewave Ltd.
- Target Recruit Count
- 27
- Registration Number
- NCT02346955
- Locations
- 🇺🇸
Call for Information (Investigational Site 0003), Los Angeles, California, United States
🇺🇸Call for Information (Investigational Site 0004), New Haven, Connecticut, United States
🇮🇱Merck Sharp & Dohme Co. Ltd., Hod Hasharon, Israel
News
No news found